Grants and Contributions:
Title:
Addressing Production and Quality Challenges in Commercializing Phage Biologics for Animal Health
Agreement Number:
1032885
Agreement Value:
$90,000.00
Agreement Date:
Aug 1, 2025 - Dec 31, 2026
Description:
This project will advance Cytophage’s Quality Assurance and Quality Control (QA/QC) systems and optimize manufacturing processes for its first bacteriophage-based animal health product. By addressing the unique production challenges of phage biologics, the project will enable GMP-certified manufacturing and support regulatory approval and commercialization of this innovative alternative to antibiotics in animal agriculture.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Oak Bluff, Manitoba, CA R4G 0B1
Reference Number:
172-2025-2026-Q2-1032885
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
838709038
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days. The total amended value is 90,000 dollars.
Amendment Date
Sep 18, 2025
Recipient's Legal Name:
Cytophage Technologies Inc.
Federal Riding Name:
Portage--Lisgar
Federal Riding Number:
46007
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
32541
Amendments: